On May 26, 2023 Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, reported it has published a poster, describing the currently enrolling phase II part of the trial MPSA-153-001, that will be presented at the upcoming ASCO (Free ASCO Whitepaper) Annual Meeting which will be held June 2-6, 2023 at the McCormick Place, Chicago, IL (Press release, Nerviano Medical Sciences, MAY 26, 2023, View Source [SID1234632180]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: "Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy"

Session Category: Trials in Progress (TIP); Poster Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Abstract Number: TPS4185

Date and Time: Monday, June 5, 2023, 8:00 AM-11:00 AM (CDT)